药理学
塞来昔布
顺铂
医学
前药
卵巢癌
血管生成
联合疗法
萘普生
活性氧
化疗
癌症研究
化学
癌症
内科学
生物化学
替代医学
病理
作者
Huijiao Fu,Peiqin Liang,Qianwen Chen,Shilong Wang,Guang Li,Xuzi Cai,Shengtao Wang,Kun Chen,Shengying Shi,Zhiqiang Yu,Xuefeng Wang
标识
DOI:10.1016/j.cclet.2023.109241
摘要
Recently, the utilization of nonsteroidal anti-inflammatory drugs (NSAIDs) to sensitize cisplatin (CDDP) has gained substantial traction in the treatment of ovarian cancer (OC). However, even widely employed NSAIDs such as celecoxib and naproxen carry an elevated risk of cardiovascular events, notably thrombosis. Furthermore, the diminished sensitivity to CDDP therapy in OC is multifactorial, rendering the application of NSAIDs only partially effective due to their cyclooxygenase-2 (COX-2) inhibiting mechanism. Hence, in this study, reactive oxygen species (ROS)-responsive composite nano-hydrangeas loaded with the Chinese medicine small molecule allicin and platinum(IV) prodrug (DTP@AP NPs) were prepared to achieve comprehensive chemosensitization. On one front, allicin achieved COX-2 blocking therapy, encompassing the inhibition of proliferation, angiogenesis and endothelial mesenchymal transition (EMT), thereby mitigating the adverse impacts of CDDP chemotherapy. Simultaneously, synergistic chemosensitization was achieved from multifaceted mechanisms by decreasing CDDP inactivation, damaging mitochondria and inhibiting DNA repair. In essence, these findings provided an optimized approach for synergizing CDDP with COX-2 inhibitors, offering a promising avenue for enhancing OC treatment outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI